Table 1

Measures of β-cell function during hypeglycemic clamp and ratio to pretreatment in the groups of type 2 diabetic patients treated with exenatide or insulin glargine

PretreatmentEnd of treatmentOff-drugEnd of treatment ratio to pretreatment (geometric mean)End of treatment ratio to pretreatment (between group difference)End of treatment ratio to pretreatment (P)Off-drug ratio to pretreatment (geometric mean)Off-drug ratio to pretreatment (between group difference)Off-drug ratio to pretreatment (P)
First-phase C-peptide response to glucose
    Glargine5.4 ± 0.66.1 ± 0.56.1 ± 0.61.17 ± 0.061.13 ± 0.05
    Exenatide5.4 ± 0.69.4 ± 1.05.0 ± 0.61.78 ± 0.111.53 ± 0.11<0.00011.00 ± 0.050.90 ± 0.060.11
Second-phase C-peptide response to glucose
    Glargine77.4 ± 8.880.7 ± 6.986.2 ± 9.11.08 ± 0.051.10 ± 0.05
    Exenatide78.5 ± 8.3235.6 ± 23.079.5 ± 9.13.05 ± 0.222.85 ± 0.22<0.00011.01 ± 0.040.92 ± 0.060.19
C-peptide response to arginine at 15 mM glucose
    Glargine20.0 ± 2.524.8 ± 2.221.4 ± 2.51.31 ± 0.071.03 ± 0.08
    Exenatide19.7 ± 2.162.2 ± 7.022.0 ± 2.63.19 ± 0.242.46 ± 0.20<0.00011.12 ± 0.061.08 ± 0.100.40
  • Data are means ± SD. Table adapted from Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ: One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 2009;32:762–768.